N
DMAC icon

Nuveen’s DiaMedica Therapeutics DMAC Stock Holding History

Nuveen’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$536K Sell
79,110
-31,918
-29% -$253K ﹤0.01% 2815
2025
Q4 		$884K Buy
111,028
+36,361
+49% +$272K ﹤0.01% 2669
2025
Q3 		$513K Buy
74,667
+40,320
+117% +$219K ﹤0.01% 2881
2025
Q2 		$134K Buy
+34,347
New +$134K ﹤0.01% 3226

Other funds holding DMAC

CLG
Cooperman Leon G $3.05B AUM 42.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture Dallas, Texas $73.6M AUM 61.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Nuveen's DMAC Position: Q1 2026 in Review

Nuveen reduced its DiaMedica Therapeutics (DMAC) stake by 29% in Q1 2026, selling an estimated $253K and leaving 79,110 shares worth $536K. The position accounts for ﹤0.01% of the portfolio, ranked #2815.

Nuveen first reported a position in DMAC in Q2 2025 and has held it in 4 quarters since. The position peaked at $884K in Q4 2025. 98 funds tracked by Wall St. Rank hold DMAC as of Q1 2026.

  • Nuveen held 79,110 shares of DiaMedica Therapeutics worth $536K as of Q1 2026.
  • Nuveen sold 31,918 DiaMedica Therapeutics shares in Q1 2026, an estimated $253K.
  • DiaMedica Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q1 2026, its #2815 holding.
  • Nuveen first reported a position in DiaMedica Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • Nuveen's DiaMedica Therapeutics position peaked at $884K in Q4 2025.
  • 98 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.